Gene Biotherapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Gene Biotherapeutics Inc. - overview
Established
2005
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2005 and led by CEO Chris Reinhard, Cardium Therapeutics specializes in developing and commercializing therapeutic products for wound healing, bone repair, and cardiovascular indications. The company specializes in solutions that serve various market needs, primarily focusing on advanced technological products and services designed for user engagement. It includes a variety of software applications focused on operational workflows, improving data analytics features, and facilitating communication across organizations. The company’s products serve various client bases that include small to medium-sized enterprises and large corporations, consisting of operational teams, and data analysts.
In addition, the firm operates in various countries such as North America, Europe, and Asia. Cardium Therapeutics developed Generx, which is an interventional cardiology, angiogenic gene therapy product for the treatment of patients with cardiac microvascular insufficiency with myocardial ischemia due to advanced coronary artery disease.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Cardiology
Website
www.cardiumthx.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.